Qureight Raises $20M to Build AI Imaging Lab for Lung and Heart Trials

Qureight raised $20M to expand its AI imaging platform for cardiopulmonary trials and will build a 3D deep learning chest imaging lab to create biomarkers for lung fibrosis, asthma, and other diseases.

• The new AI imaging laboratory will use a 3D deep learning chest foundation model to reduce imaging data and development time for new disease models.
• The company plans to expand beyond its existing lung fibrosis portfolio into asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.